First Trust Biotechnology Fund (FBT)
XMIL 
Summary
FBT Chart
2 ETFs to Watch for Outsized Volume on Biotechnology Stocks
Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund launched on June 19, 2006.
First Trust Biotechnology Fund (FBT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has First Trust Biotechnology Fund ever had a stock split?
First Trust Biotechnology Fund Profile
| XMIL Exchange | US Country |
Overview
This financial entity operates as an investment fund focusing predominantly on the biotechnology sector. It is structured to track the performance of 30 leading biotechnology companies, employing a strategic approach by allocating at least 90% of its net assets (this includes any borrowed investments) directly into the securities that form the basis of its targeted index. The index itself is constructed on an equal-dollar weighted basis, ensuring that each company within the index has an equal influence on the fund's overall performance. This method is designed to provide investors with a diversified exposure to the biotechnology industry, capturing the growth and innovation within this sector.
Products and Services
- Biotechnology Equity Investments
The primary offering of this fund revolves around equity investments in biotechnology companies. By focusing on 30 leading firms within the sector, the fund aims to tap into the growth potential of biotechnological advancements and innovations. This approach allows investors to gain exposure to a wide array of companies developing novel therapies, medical devices, and diagnostic tools, among other contributions to the healthcare sector.
Contact Information
